Integration of clinical routine data centered on tau, amyloid, and immunological pathophysiology as well as temporal disease dynamics provide a contextualized biological characterization of the ALS/FTD spectrum. The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.